Table 2.
Clinical history of the study patients
| Patient | Likely Cause of Neuropathic Pain |
Time since surgery/initial affliction (years) |
Duration of Pain (years) |
Pain Level (0-10) |
Exacerbating Factors |
Other symptoms |
Active ocular surface disease* |
Other treatments | Other neurological/psychiatric diagnosis |
|---|---|---|---|---|---|---|---|---|---|
| Refractive causes | |||||||||
| 1 | LASIK | 1 | 1 | 10 | Light | Light sensitivity | None | AT, topical loteprednol etabronate 0.5% | |
| 2 | LASIK | 2 | 2 | 10 | Light | Light sensitivity, foreign body sensation | None | AT, topical loteprednol etabronate 0.5%, topical cyclosporine 0.05% | |
| 3 | LASIK | 1 | 1 | 8 | Wind | None | None | AT, topical prednisolone acetate 1% | |
| 4 | LASIK | 0.75 | 0.5 | 10 | Use of digital devices | Redness, ocular discomfort | None | AT, topical loteprednol etabronate 0.5%, oral TCA | Depression |
| 5 | LASIK | 6 | 6 | 9 | Light | Light sensitivity | None | AT, topical loteprednol etabronate 0.5%, oral TCA | |
| 6 | LASIK | 1 | 0.5 | 9 | Wind/Cold air | Foreign body sensation | None | AT, topical prednisolone acetate 1%, oral gabapentin | Depression, Chronic pain syndrome |
| 7 | LASIK | 3 | 2 | 8 | Use of digital devices/Reading | Redness, tearing | None | AT, topical loteprednol etabronate 0.5%, topical cyclosporine | |
| 8 | LASIK | 1 | 0.8 | 10 | Light | Light sensitivity | None | AT, topical prednisolone acetate 1%, oral TCA | Depression |
| 9 | PRK | 5 | 5 | 10 | Reading | None | None | AT, topical loteprednol etabronate 0.5% | |
| Non – refractive causes | |||||||||
| 10 | Dry eye disease | 3 | 9 | Wind | Foreign body sensation | None | AT, topical cyclosporine 0.05% | Chronic pan syndrome | |
| 11 | Dry eye disease | 2 | 9 | Wind/cold air | Redness, tearing, foreign body sensation | None | AT, prednisolone acetate 1% | Fibromyalgia | |
| 12 | Dry eye disease | 2 | 8 | Use of digital devices/Reading | Redness | None | AT, prednisolone acetate 1% | ||
| 13 | Autonomic neuropathy | 2 | 9 | Reading | None | None | AT, topical loteprednol etabronate 0.5% | ||
| 14 | Herpes zoster ophthalmicus | 1 | 3 | 10 | Periocular discomfort | None | AT, topical loteprednol etabronate 0.5%, oral gabapentin | Post herpetic neuralgia | |
| 15 | UV light exposure | 0.67 | 3 | 8 | Light | Tearing, foreign body sensation | None | AT, topical loteprednol etabronate 0.5%, oral TCA | Depression |
| 16 | UV light exposure | 0.5 | 0.5 | 9 | Use of digital devices | Foreign body sensation | None | AT, topical loteprednol etabronate 0.5% |
Lasik – laser assisted in situ keratomileusis; PRK – photorefractive keratectomy; UV – ultraviolet; AT – artificial tears; TCA – tricyclic antidepressants
*
Based on Schirmer’s, Tear breakup time test and vital staining of surface